MeiraGTx Holdings Plc

MeiraGTx Holdings plc, a Nasdaq‑listed gene‑therapy pioneer, boasts a 52‑week range of $4.82–$11.85 and a $906M market cap, yet remains pre‑profit as it pushes cutting‑edge biotech therapies.

MeiraGTx Holdings, a clinical-stage gene therapy company, is making significant strides in the biotechnology industry with a robust market capitalization and a promising pipeline of innovative treatments.

MeiraGTx Holdings plc, a clinical-stage gene therapy company, has experienced a rollercoaster ride of financial and operational updates, with impressive sales growth and regulatory milestones, but also concerns about its financial health and sustain…

MeiraGTx Holdings plc is a clinical-stage gene therapy company with a diverse pipeline of preclinical and research programs, positioning it at the forefront of innovative treatments in the biotechnology sector.

MeiraGTx Holdings plc is a clinical-stage gene therapy company pioneering innovative treatments and improving patient care through its cutting-edge gene therapy solutions.

MeiraGTx Holdings plc has received FDA RMAT designation for its Parkinson’s disease treatment, AAV-GAD, a gene therapy that could bring new hope to patients with the complex neurological disorder.